Strain HN019 study
A collaborative study by Danisco and Fonterra Co-operative Group on the effects of Bifidobacterium lactis HN019 on colonic transit time (CTT) and digestive symptoms has just been published in the Scandinavian Journal of Gastroenterology.
The results of this study found that daily consumption of Bifidobacterium lactis HN019 (also known as HOWARU Bifido and DR10) decreases CTT and improves functional gastrointestinal symptoms in otherwise healthy adults.
“Gastrointestinal disorders are both common and complex. The results of this study will help us to validate the roles and benefits of consuming probiotics in patients with mild gastrointestinal disorders,” said Dr Pramod Gopal, Principal Research Scientist, Digestive and Immune Health, Fonterra Research Centre.
Poor gastrointestinal health and its complications are often linked to variances in CTT - the time it takes food to be swallowed, digested, absorbed and excreted. Functional gastrointestinal symptoms can affect the quality of daily life and include pain, bloating, diarrhoea and constipation.
In addition, published studies independent of this study indicate that slow CTT and functional GI symptoms may be associated with an increased risk of gallstones, and possibly bowel and breast cancer. Probiotic consumption may benefit people with mild gastrointestinal disorders by improving slow CTT2 and reducing associated GI symptoms.
According to European Food Safety Authority (EFSA) guidelines for digestive health claims, transit time, frequency of bowel movements and stool bulk are appropriate outcome measurements for claims on bowel function.
Phone: 02 9384 5000
A launch pad to new product development, DuPont's plant-based solutions portfolio allows food...
DuPont Nutrition & Biosciences has introduced a lactase range that can enable fermented dairy...
OptiBiotix Health Plc's SlimBiome is a patented, functional weight-loss ingredient that...